BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 26.84% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 96.21M.
Undervalued
The company’s latest PE is -451.57, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 51.34M shares, decreasing 2.40% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 454.69K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.41.